Crossject Collaborates with its Strategic Partner to Commercialize Zepizure Across Europe for the Treatment of Epileptic Seizures
Shots:
- Crossject has signed a commercialization agreement with an undisclosed strategic partner to deliver Zepizure (previously known as Zeneo) across Europe with areas incl. the UK, Germany, Denmark, Sweden, Finland, and Norway for the treatment of epileptic seizures
- Under the terms of the agreement, Crossject will receive a milestone payment of up to $1.08M upon marketing authorization granted in the territories. Moreover, Crossject covers regulatory development costs & owns potential marketing authorization while its partner will be held responsible for all commercialization costs
- Zepizure is an epileptic rescue therapy developed based on Crossject’s needle-free autoinjector Zeneo designed to enable patients and untrained caregivers to deliver emergency medication via intramuscular injection on bare skin or even through clothing
Ref: Crossject | Image: Crossject
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
